RankAlpha logo
Back to Rankings

CTNM

Contineum TherapeuticsD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
View Chart
Current thesis
The constructive case is balance-sheet-backed optionality around PIPE-791: patient dosing has started in PROPEL-IPF, chronic-pain topline is due in Q2 2026, and cash runway extends into mid-2029, giving CTNM time to reach more meaningful clinical inflections without obvious near-term financing stress [#PR-2026-03-05][#10-K-2026-03-05].
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +8.8.
What can break
Cash runway is improved but not permanent; clinical setbacks could reopen dilution risk.
Momentum
65
Value
41
Sentiment
39
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $13.00 · Bull $19.00 · Bear $8.00
Data freshness
Prices
As of 2026-07-22
Fundamentals
As of 2026-07-22 • Vendor: Data Vendor v1
Scores
As of 2026-07-22 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-22
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $22.33
Why
Momentum65 · Δ7d +8.8
Value41 · Δ7d -0.0
Sentiment39 · Δ7d +3.9
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
65
26% active weight
Current posture
7d trendSoftening
Δ7d
+8.8
Δ21d
+45.6
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.1
Sentiment
39
34% active weight
Current posture
7d trendImproving
Δ7d
+3.9
Δ21d
+12.8
Why this grade

Composite grade D. Momentum 64.9 / Value 41.1 / Sentiment 38.7

Fundamentals (TTM)
As of 2026-07-22
Market Cap
$550.7M
Beta
-
Shares Out
37.39M
P/E (TTM) · Derived
-6.8
P/S (TTM)
-
P/FCF (TTM) · Derived
-7.69
Rev YoY
-100.0%
EPS YoY
-37.4%
Gross Margin
+99.6%
Op Margin
-
Net Debt
-$254.65M
Current Ratio
38.00
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology